Fra­zier adds $780M fund for its ‘growth buy­out’ team; FDA push­es back its dead­line on Ab­b­Vie's elagolix; Promethera buys NASH drug

→ Fra­zier Health­care Part­ners has put to­geth­er a $780 mil­lion fund for its “growth buy­out” group to in­vest. A busy life sci­ences in­vestor, this new fund is their sec­ond aimed at prof­itable health­care com­pa­nies in the low­er end of the mid­dle mar­ket. Fra­zier, with of­fices in Sil­i­con Val­ley and Seat­tle, planned to in­vest this mon­ey in health­care and phar­ma­ceu­ti­cal ser­vices, med­ical prod­ucts and re­lat­ed sec­tors. “We are ap­pre­cia­tive of the con­tin­ued sup­port from our ex­ist­ing in­vestors and pleased to have added a few new se­lect blue-chip lim­it­ed part­ners that to­geth­er rep­re­sent a world-class group of in­vestors,” said Nad­er Nai­ni, man­ag­ing part­ner at Fra­zier Health­care Part­ners. “The com­mit­ment and con­fi­dence they have shown in our team is di­rect­ly re­lat­ed to our rich 27-year his­to­ry of de­vel­op­ing cat­e­go­ry-lead­ing health­care com­pa­nies. The team is par­tic­u­lar­ly grat­i­fied by the over­whelm­ing re­sponse to this of­fer­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER